Welcome, this website is intended for international healthcare professionals with an interest in the treatment of Advanced Prostate Cancer. By clicking the link below you are declaring and confirming that you are a healthcare professional

You are here

PREVAIL trial: post-hoc analysis update

Esmo 3 PREVAIL trial- post-hoc analysis update

The experts discussed the results of the post-hoc analysis of the PREVAIL study which showed that there is a subset of men in whom there is radiological progression even when the prostate specific antigen (PSA) limits are in the range. They further discussed the importance of reimaging in such scenarios and the schedule of reimaging that should be followed. They emphasized on the need for standard guidelines for imaging in the management of prostate cancer.

Next video

Additional materials:

  • Resources on Castration:

    Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials

    Eur J Cancer 2016 Jul;61:111-21.

    Link to full article text: Role of the novel generation of androgen receptor pathway targeted agents in the management of castration-resistant prostate cancer: A literature based meta-analysis of randomized trials


    Advances in the management of castration resistant prostate cancer

    Ritch CR, Cookson MS

    BMJ 2016;355:i4405.

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/2775484


     A post hoc analysis of radiographic progression with nonrising prostate-specific antigen in patients with metastatic castration-resistant prostate cancer (mCRPC) in the PREVAIL study

    Bryce et al.

    Annals of Oncology 27 (Supplement 6): vi243–vi265, 2016

    Link to full article text: http://annonc.oxfordjournals.org/content/27/suppl_6/760P.full.pdf

  • Resources on Abiraterone:

    Abiraterone in metastatic prostate cancer without previous chemotherapy

    Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al.

    N Engl J Med 2013 ;368:138-48.

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/23228172


    Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al.

    Lancet Oncol 2015;16:152-60

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/25601341


    Abiraterone and increased survival in metastatic prostate cancer

    de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al.

    N Engl J Med 2011;364:1995-2005.

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/21612468


    Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al.

    Lancet Oncol 2012;13:983-92

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/22995653


    Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status

    Eur Urol 2015;67:441-7

    Link to full article text: Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status


    745P: Treatment options in advanced castration-resistant, docetaxel-resistant prostate cancer (ACRDRPC). Final results of a network meta-analysis

  • Resources on Enzalutamide:

    Increased survival with enzalutamide in prostate cancer after chemotherapy

    Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al.

    NEJM 2012;367:1187-97

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/22894553


    Enzalutamide in metastatic prostate cancer before chemotherapy

    Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al.

    NEJM 2014;371:424-33

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/24881730


    Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study

    Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, et al

    Lancet Oncol 2016;17:153-63

    Link to full article text: https://www.ncbi.nlm.nih.gov/pubmed/26774508


    745P: Treatment options in advanced castration-resistant, docetaxel-resistant prostate cancer (ACRDRPC). Final results of a network meta-analysis

  • Longer term follow-up studies on survival outcomes with novel androgen inhibitors:

    743P: Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study


    748P: Switch from abiraterone + prednisone to abiraterone + dexamethasone after PSA progression under abiraterone + prednisone in asymptomatic metastatic castration-resistant prostate cancer (mCRPC) patients